Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7303423 | 0.87 | QDPR (0.51) | SIGMAR1HTR1APARP1 | |
| SCHEMBL7296057 | 0.87 | SIGMAR1 (0.61) | SIGMAR1HTR1APARP1HTR7 | |
| SCHEMBL7306525 | 0.87 | SIGMAR1 (0.61) | SIGMAR1HTR1APARP1SMN1; SMN2 | |
| SCHEMBL7304853 | 0.87 | SIGMAR1 (0.58) | SIGMAR1HTR1A | |
| SCHEMBL6635917 | 0.81 | SIGMAR1 (0.61) | SIGMAR1HTR1APARP1HTR7 | |
| SCHEMBL7292781 | 0.79 | SIGMAR1 (0.64) | SIGMAR1HTR1APARP1HTR7 | |
| SCHEMBL6434881 | 0.77 | SIGMAR1 (0.57) | SIGMAR1HTR1APARP1HTR7 | |
| SCHEMBL6373489 | 0.75 | SIGMAR1 (0.55) | SIGMAR1HTR1APARP1HTR7 | |
| SCHEMBL14144244 | 0.75 | SIGMAR1 (0.54) | SIGMAR1HTR1APARP1 | |
| SCHEMBL7294958 | 0.74 | QDPR (0.55) | SIGMAR1HTR1APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | disclosed |
| EP-2646025-B1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | ESTEVE LABOR DR (ES) | 2017-03-15 | — | — | EP | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| EP-2460519-A1 | Use of sigma ligands in bone cancer pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | disclosed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |